CTRV - ContraVir Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.69
-0.02 (-2.82%)
At close: 3:58PM EDT

0.70 +0.01 (1.45%)
After hours: 6:01PM EDT

Stock chart is not supported by your current browser
Previous Close0.71
Open0.73
Bid0.68 x 900
Ask0.70 x 800
Day's Range0.67 - 0.73
52 Week Range0.61 - 6.60
Volume339,233
Avg. Volume330,898
Market Cap9.972M
Beta0.47
PE Ratio (TTM)N/A
EPS (TTM)-1.41
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire15 hours ago

    ContraVir Pharmaceuticals Announces Completion of Phase 1 with CRV431

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today that the primary endpoints of safety and tolerability were met in a single ascending dose (SAD) study of CRV431 conducted in the United States. Subjects in the study were treated with escalating doses of CRV431 administered as a single dose.  In addition to a favorable safety and tolerability profile, pharmacokinetic (PK) profiling demonstrated CRV431 exposure levels that are anticipated to be efficacious in future HBV patient studies. “The positive results from this trial support the continued development of CRV431 in a Phase 2 clinical efficacy study.

  • GlobeNewswire20 days ago

    ContraVir Pharmaceuticals Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018

    EDISON, N.J., Aug. 30, 2018-- ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus, ...

  • GlobeNewswirelast month

    ContraVir Pharmaceuticals Completes Data Analysis of Second Cohort in Part 1 of the Phase 1/2a Study of CRV431

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today that the second cohort in Part 1 of the Phase 1/2a trial of CRV431 has been completed. CRV431, the other anti-HBV compound, is a host-targeting antiviral (HTA) next-generation cyclophilin inhibitor with a novel chemical structure that optimizes the selective index against HBV. In vitro and in vivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins, including surface antigen (HBsAg), while offering additional benefits to mitigate liver disease.

  • GlobeNewswirelast month

    ContraVir Pharmaceuticals Provides an Update to Corporate Objectives

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced an update on its business activities to date. “2018 has brought a plethora of positive and exciting announcements placing ContraVir as one of the few companies with two clinical assets fighting against the hepatitis B virus,” said James Sapirstein, Chief Executive Officer at ContraVir. “Our team has been working diligently to hit anticipated milestones and accelerate the development of our programs.

  • ContraVir Stock Rose on Clinical Trial Progress Report
    Market Realist2 months ago

    ContraVir Stock Rose on Clinical Trial Progress Report

    On July 23, ContraVir Pharmaceuticals stock closed at $0.95, which represents ~12% growth from its 52-week low of $0.85 on July 20 and 4.7% growth from its close of $0.91 on July 20. ContraVir Pharmaceuticals hit its 52-week high of $6.60 on October 17, 2017. On July 23, ContraVir Pharmaceuticals stock started rising after the company gave an update on its phase 1/2A trial of CRV431.

  • GlobeNewswire2 months ago

    ContraVir Pharmaceuticals Reports Progress in Phase 1/2A Trial of CRV431

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today that it has completed dosing of the first cohort in Part 1 of the Phase 1/2A trial of CRV431.  Preliminary data from the first completed cohort suggest that CRV431 is safe and well-tolerated. “Initial data from the first dosing cohort in Part 1 of the Phase 1/2A trial of CRV431 was encouraging, with results indicating the drug is safe and yields a pharmacokinetic profile suggesting favorable oral bioavailability,” said James Sapirstein, Chief Executive Officer of ContraVir.

  • PR Newswire2 months ago

    Live Investor Conference & Webinar: NASDAQ and OTC companies to present live on July 12th

    Company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , July 10, 2018 /PRNewswire/ -- PR Newswire and BetterInvesting (NAIC) today announced the agenda for the ...

  • PR Newswire2 months ago

    ContraVir Pharmaceuticals to Present at Virtual Investor Conference

    Live Webcast Scheduled for July 12, 2018, 10:00 AM ET, followed by Q&A EDISON, N.J. , July 5, 2018 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on ...

  • GlobeNewswire3 months ago

    ContraVir Pharmaceuticals Announces $10.8 Million in Expected Gross Proceeds from Recently Expired Rights Offering

    ContraVir Pharmaceuticals, Inc. (CTRV) (“ContraVir” or the “Company”), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today that the Company’s previously announced rights offering (“the Rights Offering”) expired on Thursday, June 28, 2018 and these rights are no longer exercisable. The Company accepted all valid subscriptions that were presented and estimates that the Rights Offering will result in approximately $10.8 million in gross proceeds.

  • GlobeNewswire3 months ago

    ContraVir Pharmaceuticals Initiates Dosing of CRV431 in First In-Human Trial

    The randomized, partially-blinded, placebo-controlled ascending sequential dose group study will assess safety, tolerability and pharmacokinetics (PK) of CRV431 in healthy volunteers as part 1 of the first clinical study. Part two of the clinical trial will consist of a single dose of CRV431 in a drug to drug interaction study assessing the safety, tolerability and PK co-administered with Viread® (tenofovir disoproxil fumarate), and part three of the study will assess the safety, tolerability, PK and preliminary signal for antiviral efficacy of CRV431 in stable HBV patients already treated with Viread®.

  • GlobeNewswire3 months ago

    ContraVir Pharmaceuticals Announces Data on Optimized Formulation of TXL™

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today the company has chosen an optimized formulation of tenofovir exalidex (TXL™) and is ready to initiate dosing HBV patients in a dose-range finding study with the optimized formulation. TXL™ has been designed to target the liver to deliver the active drug to the reservoir where the hepatitis B virus resides.